Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
Sponsor: Amgen
Summary
The primary objective of this study is to evaluate the long-term safety of apremilast in subjects 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic arthritis that have completed Study 20190530 or Study 20190529.
Official title: A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet's Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis
Key Details
Gender
All
Age Range
5 Years - 18 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2023-03-23
Completion Date
2036-03-17
Last Updated
2025-12-01
Healthy Volunteers
No
Interventions
Apremilast
Oral tablets or liquid suspension
Locations (7)
General Hospital of Thessaloniki Ippokrateio
Thessaloniki, Greece
Meir Medical Center
Kfar Saba, Israel
Hospital Universitari i Politecnic La Fe
Valencia, Valencia, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hacettepe Universitesi Tip Fakultesi Hastanesi
Ankara, Turkey (Türkiye)
Istanbul Universitesi Cerrahpasa Tip Fakultesi
Istanbul, Turkey (Türkiye)
Umraniye Egitim ve Arastirma Hastanesi
Istanbul, Turkey (Türkiye)